PTPsemerge as PIPs: Protein tyrosine phosphatases with lipid-phosphatase activities in human disease

Human Molecular Genetics

Volumn 22, Issue R1, 2013, Pages

  Pulido, Rafael ^a,b   Stoker, Andrew W ^c   Hendriks, Wiljan J A J ^d  

^a BIOCRUCES BIZKAIA HEALTH RESEARCH INSTITUTE   (Spain)

^b BASQUE FOUNDATION FOR SCIENCE   (Spain)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LIPID PHOSPHATASE; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE; UNCLASSIFIED DRUG; PHOSPHOLIPID;

ARTICLE; ASTHMA; CREUTZFELDT JAKOB DISEASE; DISEASES; DOWN SYNDROME; DRUG DEPENDENCE; DUANE RETRACTION SYNDROME; ENZYME ACTIVITY; GENETIC DISORDER; HUMAN; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; SARCOPENIA; AMINO ACID SEQUENCE; ANTAGONISTS AND INHIBITORS; CHEMISTRY; ENZYME SPECIFICITY; ENZYMOLOGY; GENETICS; METABOLISM; MOLECULAR GENETICS; MUSCLE DISEASE; NEOPLASMS; NEUROLOGIC DISEASE; PATHOLOGY; PHOSPHORYLATION; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; DRUG ANTAGONISM; REVIEW;

AMINO ACID SEQUENCE; HUMANS; MOLECULAR SEQUENCE DATA; MUSCULAR DISEASES; NEOPLASMS; NERVOUS SYSTEM DISEASES; PHOSPHOLIPIDS; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASES; SEQUENCE ALIGNMENT; SIGNAL TRANSDUCTION; SUBSTRATE SPECIFICITY;

EID: 84884772860     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddt347     Document Type: Article

References (107)

1. Alonso, A., Sasin, J., Bottini, N., Friedberg, I., Friedberg, I., Osterman, A., Godzik, A., Hunter, T., Dixon, J. and Mustelin, T. (2004) Protein tyrosine phosphatases in the human genome. Cell, 117, 699-711.
2. Li, X., Wilmanns, M., Thornton, J., and Kohn,M.(2013) Elucidatinghuman phosphatase-substrate networks. Sci. Signal., 6, rs10.
3. Dyson, J.M., Fedele, C.G., Davies, E.M., Becanovic, J., and Mitchell, C.A. (2012) Phosphoinositide phosphatases: just as important as the kinases. Subcell. Biochem., 58, 215-279.
4. Hendriks, W.J., Elson, A., Harroch, S., Pulido, R., Stoker, A., and den Hertog, J. (2013) Protein tyrosine phosphatases in health, and disease.FEBS J., 280, 708-730.
5. Hendriks, W.J., Elson, A., Harroch, S., and Stoker, A.W. (2008) Protein tyrosine phosphatases: functional inferences from mouse models, and human diseases. FEBS J., 275, 816-830.
6. Liu, Y., and Bankaitis, V.A. (2010) Phosphoinositide phosphatases in cell biology, and disease. Prog. Lipid Res., 49, 201-217.
7. Pulido, R., and Hooft van Huijsduijnen, R. (2008) Protein tyrosine phosphatases: dual-specificity phosphatases in health, and disease.FEBSJ., 275, 848-866.
8. Caromile, L.A., Oganesian, A., Coats, S.A., Seifert, R.A., and Bowen-Pope, D.F. (2010) The neurosecretory vesicle protein phogrin functions as a phosphatidylinositol phosphatase to regulate insulin secretion. J. Biol. Chem., 285, 10487-10496.
9. Oganesian, A., Poot, M.,Daum,G., Coats, S.A., Wright, M.B., Seifert, R.A., and Bowen-Pope, D.F. (2003) Protein tyrosine phosphatase RQ is a phosphatidylinositol phosphatase that can regulate cell survival, and proliferation. Proc. Natl Acad. Sci. USA, 100, 7563-7568.
10. Wright, M.B., Hugo, C., Seifert, R., Disteche, C.M., and Bowen-Pope, D.F. (1998) Proliferating, and migrating mesangial cells responding to injury express a novel receptor protein-tyrosine phosphatase in experimental mesangial proliferative glomerulonephritis. J. Biol. Chem., 273, 23929- 23937.
11. Seifert, R.A., Coats, S.A., Oganesian, A., Wright, M.B., Dishmon, M., Booth, C.J., Johnson, R.J., Alpers, C.E., and Bowen-Pope, D.F. (2003) PTPRQ is a novel phosphatidylinositol phosphatase that can be expressed as a cytoplasmic protein or as a subcellularly localized receptor-like protein. Exp. Cell Res., 287, 374-386.
12. Schraders, M., Oostrik, J., Huygen, P.L., Strom, T.M., van Wijk, E., Kunst, H.P., Hoefsloot, L.H., Cremers, C.W., Admiraal, R.J., and Kremer, H. (2010) Mutations in PTPRQ are a cause of autosomal-recessive nonsyndromic hearing impairmentDFNB84and associated with vestibular dysfunction. Am. J. Hum. Genet., 86, 604-610.
13. Jung, H., Kim, W.K., Kim do, H., Cho, Y.S., Kim, S.J., Park, S.G., Park, B.C., Lim, H.M., Bae, K.H., and Lee, S.C. (2009) Involvement of PTP-RQ in differentiation during adipogenesis of human mesenchymal stem cells. Biochem. Biophys. Res. Commun., 383, 252-257.
14. Goodyear, R.J., Legan, P.K., Wright, M.B., Marcotti, W., Oganesian, A., Coats, S.A., Booth, C.J., Kros, C.J., Seifert, R.A., Bowen-Pope, D.F. et al. (2003) A receptor-like inositol lipid phosphatase is required for the maturation of developing cochlear hair bundles. J. Neurosci., 23, 9208- 9219.
15. Sakaguchi, H., Tokita, J., Naoz, M., Bowen-Pope, D., Gov, N.S., and Kachar, B. (2008) Dynamic compartmentalization of protein tyrosine phosphatase receptor Q at the proximal end of stereocilia: implication of myosin VI-based transport. Cell Motil. Cytoskeleton, 65, 528-538.
16. van Reeuwijk, J., Arts, H.H., and Roepman, R. (2011) Scrutinizing ciliopathies by unraveling ciliary interaction networks. Hum. Mol. Genet., 20, R149-R157.
17. Shahin, H., Rahil, M.,AbuRayan, A., Avraham, K.B., King, M.C., Kanaan, M., and Walsh, T. (2010) Nonsense mutation of the stereociliar membrane protein gene PTPRQ in human hearing loss DFNB84. J. Med. Genet., 47, 643-645.
18. Aricescu, A.R., Siebold, C., Choudhuri, K., Chang, V.T., Lu, W., Davis, S.J., van der Merwe, P.A., and Jones, E.Y. (2007) Structure of a tyrosine phosphatase adhesive interaction reveals a spacer-clamp mechanism. Science, 317, 1217-1220.
19. Abu-Amero, K.K., Kondkar, A.A., Salih, M.A., Alorainy, I.A., Khan, A.O., Oystreck, D.T., and Bosley, T.M. (2013) Partial chromosome 7 duplication with a phenotype mimicking the HOXA1 spectrum disorder. Ophthalmic Genet., 34, 90-96.
20. Cai, T., Hirai, H., Zhang, G., Zhang, M., Takahashi, N., Kasai, H., Satin, L.S., Leapman, R.D., and Notkins, A.L. (2011) Deletion of Ia-2 and/or Ia-2beta in mice decreases insulin secretion by reducing the number of dense core vesicles. Diabetologia, 54, 2347-2357.
21. Mandemakers, W., Abuhatzira, L., Xu, H., Caromile, L.A., Hebert, S.S., Snellinx, A., Morais, V.A., Matta, S., Cai, T., Notkins, A.L. et al. (2013) Co-regulation of intragenicmicroRNAmiR-153, and its host gene Ia-2 beta: identification of miR-153 target genes with functions related to IA-2beta in pancreas, and brain. Diabetologia, 56, 1547-1556.
22. Davies, E.M., Sheffield, D.A., Tibarewal, P., Fedele, C.G., Mitchell, C.A., and Leslie, N.R. (2012) The PTEN, and myotubularin phosphoinositide 3-phosphatases: linking lipid signalling to human disease. Subcell. Biochem., 58, 281-336.
23. Huang, H., Cheville, J.C., Pan, Y., Roche, P.C., Schmidt, L.J., and Tindall, D.J. (2001) PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J. Biol. Chem., 276, 38830-38836.
24. Nagata, Y., Lan, K.H., Zhou, X., Tan, M., Esteva, F.J., Sahin, A.A., Klos, K.S., Li, P., Monia, B.P., Nguyen, N.T. et al. (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell, 6, 117-127.
25. Nair, J.S., Sheikh, T., Ho, A.L., and Schwartz, G.K. (2013) PTEN regulates sensitivity of melanoma cells to RO4929097, the gamma-secretase inhibitor. Anticancer Res., 33, 1307-1316.
26. Hollander, M.C., Blumenthal, G.M., and Dennis, P.A. (2011) PTEN loss in the continuum ofcommoncancers, rare syndromes, and mouse models. Nat. Rev. Cancer, 11, 289-301.
27. Song, M.S., Salmena, L., and Pandolfi, P.P. (2012) The functions, and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol., 13, 283-296.
28. Leslie, N.R., Maccario, H., Spinelli, L., and Davidson, L. (2009) The significance of PTEN's protein phosphatase activity. Adv. Enzyme Regul., 49, 190-196.
29. Zhang, X.C., Piccini, A., Myers, M.P., Van Aelst, L., and Tonks, N.K. (2012) Functional analysis of the protein phosphatase activity of PTEN. Biochem. J., 444, 457-464.
30. Davidson, L., Maccario, H., Perera, N.M., Yang, X., Spinelli, L., Tibarewal, P., Glancy, B., Gray, A., Weijer, C.J., Downes, C.P. et al. (2010) Suppression of cellular proliferation, and invasionby the concerted lipid, and protein phosphatase activities of PTEN. Oncogene, 29, 687-697.
31. Myers, M.P., Pass, I., Batty, I.H., Van der Kaay, J., Stolarov, J.P., Hemmings, B.A., Wigler, M.H., Downes, C.P., and Tonks, N.K. (1998) The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc. Natl Acad. Sci. USA, 95, 13513-13518.
32. Sotelo, N.S., Valiente, M., Gil, A., and Pulido, R. (2012) A functional network of the tumor suppressors APC, hDlg, and PTEN, that relies on recognition of specific PDZ-domains. J. Cell Biochem., 113, 2661-2670.
33. Mester, J., and Eng, C. (2013) When overgrowth bumps into cancer: the PTEN-opathies. Am. J. Med. Genet. C Semin. Med. Genet., 163, 114-121.
34. Rodríguez-Escudero, I., Oliver, M.D., Andrés-Pons, A., Molina, M., Cid, V.J., and Pulido, R. (2011) A comprehensive functional analysis of PTEN mutations: implications in tumor-, and autism-related syndromes. Hum. Mol. Genet., 20, 4132-4142.
35. Tan, M.H., Mester, J., Peterson, C., Yang, Y., Chen, J.L., Rybicki, L.A., Milas, K., Pederson, H., Remzi, B., Orloff, M.S., et al. (2011) A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. Am. J. Hum. Genet., 88, 42-56.
36. Tan, M.H., Mester, J., Peterson, C., Yang, Y., Chen, J.L., Rybicki, L.A., Milas, K., Pederson, H., Remzi, B., Orloff, M.S., et al. (2012) A clinical scoring system for selection of patients for PTEN mutation testing is proposed on the basis of a prospective study of 3042 probands. Am. J. Hum. Genet., 88, 42-56.
37. Galatola, M., Paparo, L., Duraturo, F., Turano, M., Rossi, G.B., Izzo, P., and De Rosa, M. (2012) Beta catenin, and cytokine pathway dysregulation in patients with manifestations of the 'PTEN hamartoma tumor syndrome'. BMC Med. Genet., 13, 28.
38. Hobert, J.A., Mester, J.L., Moline, J., and Eng, C. (2012) Elevated plasma succinate in PTEN, SDHB, and SDHD mutation-positive individuals. Genet. Med., 14, 616-619.
39. Ngeow, J., He, X., Mester, J.L., Lei, J., Romigh, T., Orloff, M.S., Milas, M., and Eng, C. (2012) Utility of PTEN protein dosage in predicting for underlying germline PTEN mutations among patients presenting with thyroid cancer, and Cowden-like phenotypes. J. Clin. Endocrinol. Metab., 97, E2320-E2327.
40. Tran, L.M., Chang, C.J., Plaisier, S., Wu, S., Dang, J., Mischel, P.S., Liao, J.C., Graeber, T.G., and Wu, H. (2012) DeterminingPTENfunctional status by network component deduced transcription factor activities. PLoS ONE, 7, e31053.
41. Keyes, K.T., Xu, J., Long, B., Zhang, C., Hu, Z., and Ye, Y. (2010) Pharmacological inhibition of PTEN limits myocardial infarct size, and improves left ventricular function postinfarction. Am. J. Physiol. Heart Circ. Physiol., 298, H1198-H1208.
42. Lai, J.P., Bao, S., Davis, I.C., and Knoell, D.L. (2009) Inhibition of the phosphatase PTEN protects mice against oleic acid-induced acute lung injury. Br. J. Pharmacol., 156, 189-200.
43. Garcia-Cao, I., Song, M.S., Hobbs, R.M., Laurent, G., Giorgi, C., de Boer, V.C., Anastasiou, D., Ito, K., Sasaki, A.T., Rameh, L., et al. (2012) Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell, 149, 49-62.
44. Ortega-Molina, A., Efeyan, A., Lopez-Guadamillas, E., Muñoz-Martin, M., Gomez-Lopez, G., Cañamero, M., Mulero, F., Pastor, J., Martinez, S., Romanos, E., et al. (2012) Pten positively regulates brown adipose function, energy expenditure, and longevity. Cell Metab., 15, 382-394.
45. Pal, A., Barber, T.M., Van de Bunt, M., Rudge, S.A., Zhang, Q., Lachlan, K.L., Cooper, N.S., Linden, H., Levy, J.C., Wakelam, M.J., et al. (2012) PTENmutations as a cause of constitutive insulin sensitivity, and obesity. N. Engl. J. Med., 367, 1002-1011.
46. Wong, J.T., Kim, P.T., Peacock, J.W., Yau, T.Y., Mui, A.L., Chung, S.W., Sossi, V., Doudet, D., Green, D., Ruth, T.J., et al. (2007) Pten (phosphatase, and tensin homologue gene) haploinsufficiency promotes insulin hypersensitivity. Diabetologia, 50, 395-403.
47. Pezzolesi, M.G., Platzer, P., Waite, K.A., and Eng, C. (2008) Differential expression of PTEN-targeting microRNAs miR-19a, and miR-21 in Cowden syndrome. Am. J. Hum. Genet., 82, 1141-1149.
48. Lee, K.S., Park, S.J., Hwang, P.H., Yi, H.K., Song, C.H., Chai, O.H., Kim, J.S., Lee, M.K., and Lee, Y.C. (2005) PPAR-gamma modulates allergic inflammation through up-regulation of PTEN. FASEB J., 19, 1033-1035.
49. Waite, K.A., Sinden, M.R., and Eng, C. (2005) Phytoestrogen exposure elevates PTEN levels. Hum. Mol. Genet., 14, 1457-1463.
50. Leslie, N.R., and Foti, M. (2011) Non-genomic loss of PTEN function in cancer: not in my genes. Trends Pharmacol. Sci., 32, 131-140.
51. Andrés-Pons, A., Gil, A., Oliver, M.D., Sotelo, N.S., and Pulido, R. (2012) Cytoplasmic p27Kip1 counteracts the pro-apoptotic function of the open conformation of PTEN by retention, and destabilization of PTEN outside of the nucleus. Cell Signal., 24, 577-587.
52. Gil, A., Andres-Pons, A., and Pulido, R. (2007) Nuclear PTEN: a tale of many tails. Cell Death Differ, 14, 395-399.
53. Huang, J., Yan, J., Zhang, J., Zhu, S., Wang, Y., Shi, T., Zhu, C., Chen, C., Liu, X., Cheng, J., et al. (2012) SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membrane. Nat. Commun., 3, 911.
54. Putz, U., Howitt, J., Doan, A., Goh, C.P., Low, L.H., Silke, J., and Tan, S.S. (2012) The tumor suppressor PTEN is exported in exosomes, and has phosphatase activity in recipient cells. Sci. Signal., 5, ra70.
55. Hopkins, B.D., Fine, B., Steinbach, N., Dendy, M., Rapp, Z., Shaw, J., Pappas, K., Yu, J.S., Hodakoski, C., Mense, S., et al. (2013) A secreted PTEN phosphatase that enters cells to alter signaling, and survival. Science, 341, 399-402.
56. Naguib, A., and Trotman, L.C. (2013) PTEN plasticity: how the taming of a lethal gene can go too far. Trends Cell Biol., 23, 374-9.
57. Sutton, K.A., Jungnickel, M.K., Jovine, L., and Florman, H.M. (2012) Evolution of the voltage sensor domain of the voltage-sensitive phosphoinositide phosphatase VSP/TPTE suggests a role as a proton channel in eutherian mammals. Mol. Biol. Evol., 29, 2147-2155.
58. Tapparel, C., Reymond, A., Girardet, C., Guillou, L., Lyle, R., Lamon, C., Hutter, P., and Antonarakis, S.E. (2003) The TPTE gene family: cellular expression, subcellular localization, and alternative splicing. Gene, 323, 189-199.
59. Walker, S.M., Downes, C.P., and Leslie, N.R. (2001) TPIP: a novel phosphoinositide 3-phosphatase. Biochem. J., 360, 277-283.
60. Shaw, S.W., Chen, C.P., Cheng, P.J., Wang, T.H., Hou, J.W., Lin, C.T., Chang, S.D., Hwa, H.L., Lin, J.L., Chao, A.S., et al. (2008) Gene dosage change of TPTE, and BAGE2, and breakpoint analysis in Robertsonian Down syndrome. J. Hum. Genet., 53, 136-143.
61. Halaszovich, C.R., Leitner, M.G., Mavrantoni, A., Le, A., Frezza, L., Feuer, A., Schreiber, D.N., Villalba-Galea, C.A., and Oliver, D. (2012) A human phospholipid phosphatase activated by a transmembrane control module. J. Lipid Res., 53, 2266-2274.
62. Mishra, R.R., Chaudhary, J.K., Bajaj, G.D., and Rath, P.C. (2011) A novel human TPIP splice-variant (TPIP-C2) mRNA, expressed in human, and mouse tissues, strongly inhibits cell growth in HeLa cells. PLoS ONE, 6, e28433.
63. Mishra, R.R., Chaudhary, J.K., and Rath, P.C. (2012) Cell cycle arrest, and apoptosis by expression of a novel TPIP (TPIP-C2) cDNA encoding a C2-domain in HEK-293 cells. Mol. Biol. Rep., 39, 7389-7402.
64. Robinson, F.L., and Dixon, J.E. (2006) Myotubularin phosphatases: policing 3-phosphoinositides. Trends Cell Biol., 16, 403-412.
65. Lecompte, O., Poch, O., and Laporte, J. (2008) PtdIns5P regulation through evolution: roles in membrane trafficking? Trends Biochem. Sci., 33, 453- 460.
66. Amoasii, L., Hnia, K., Chicanne, G., Brech, A., Cowling, B.S., Muller, M.M., Schwab, Y., Koebel, P., Ferry, A., Payrastre, B., et al. (2012) Myotubularin, and PtdIns3P remodel the sarcoplasmic reticulum in muscle in vivo. J. Cell Sci., 126, 1806-1819.
67. Hnia, K., Vaccari, I., Bolino, A., and Laporte, J. (2012) Myotubularin phosphoinositide phosphatases: cellular functions, and disease pathophysiology. Trends Mol. Med., 18, 317-327.
68. Romero-Suarez, S., Shen, J., Brotto, L., Hall, T., Mo, C., Valdivia, H.H., Andresen, J., Wacker, M., Nosek, T.M., Qu, C.K., et al. (2010) Muscle-specific inositide phosphatase (MIP/MTMR14) is reduced with age, and its loss accelerates skeletal muscle aging process by altering calcium homeostasis. Aging (Albany, NY), 2, 504-513.
69. Clague, M.J., Dove, S.K., and Barr, F.A. (2004) I-proteins - a proposed switch in myotubularin function. Trends Biochem. Sci., 29, 58-61.
70. Amoasii, L., Bertazzi, D.L., Tronchere, H., Hnia, K., Chicanne, G., Rinaldi, B., Cowling, B.S., Ferry, A., Klaholz, B., Payrastre, B., et al. (2012) Phosphatase-dead myotubularin ameliorates X-linked centronuclear myopathy phenotypes in mice. PLoS Genet., 8, e1002965.
71. Amburgey, K., Lawlor, M.W., Del Gaudio, D., Cheng, Y.W., Fitzpatrick, C., Minor, A., Li, X., Aughton, D., Das, S., Beggs, A.H., et al. (2013) Large duplication in MTM1 associated with myotubular myopathy. Neuromuscul. Disord., 23, 214-218.
72. Al-Qusairi, L., Prokic, I., Amoasii, L., Kretz, C., Messaddeq, N., Mandel, J.L., and Laporte, J. (2013) Lack of myotubularin (MTM1) leads to musclehypotrophy through unbalanced regulation of the autophagy, and ubiquitin-proteasome pathways. FASEB J., 27, 3384-3394.
73. Fetalvero, K.M., Yu, Y., Goetschkes, M., Liang, G., Valdez, R.A., Gould, T., Triantafellow, E., Bergling, S., Loureiro, J., Eash, J., et al. (2013) Defective autophagy, and mTORC1 signaling in myotubularin null mice. Mol. Cell Biol., 33, 98-110.
74. Joubert, R., Vignaud, A., Le, M., Moal, C., Messaddeq, N., and Buj-Bello, A. (2013) Site-specific Mtm1 mutagenesis by an AAV-Cre vector reveals that myotubularin is essential in adult muscle.Hum.Mol. Genet., 22, 1856- 1866.
75. Berger, P., Berger, I., Schaffitzel, C., Tersar, K., Volkmer, B., and Suter, U. (2006) Multi-level regulation of myotubularin-related protein-2 phosphatase activity by myotubularin-related protein-13/set-binding factor-2. Hum. Mol. Genet., 15, 569-579.
76. Robinson, F.L., and Dixon, J.E. (2005) The phosphoinositide-3-phosphatase MTMR2 associates with MTMR13, a membrane-associated pseudophosphatase also mutated in type 4B Charcot-Marie-Tooth disease. J. Biol. Chem., 280, 31699-31707.
77. Bolino, A., Bolis, A., Previtali, S.C., Dina, G., Bussini, S., Dati, G., Amadio, S., Del Carro, U., Mruk, D.D., Feltri, M.L., et al. (2004) Disruption of Mtmr2 produces CMT4B1-like neuropathy with myelin outfolding, and impaired spermatogenesis. J. Cell Biol., 167, 711-721.
78. Bonneick, S., Boentert, M., Berger, P., Atanasoski, S., Mantei, N., Wessig, C., Toyka, K.V., Young, P., and Suter, U. (2005) An animal model for Charcot-Marie-Tooth disease type 4B1. Hum. Mol. Genet., 14, 3685- 3695.
79. Robinson, F.L., Niesman, I.R., Beiswenger, K.K., and Dixon, J.E. (2008) Loss of the inactive myotubularin-related phosphatase Mtmr13 leads to a Charcot-Marie-Tooth 4B2-like peripheral neuropathy in mice. Proc. Natl Acad. Sci. USA, 105, 4916-4921.
80. Tersar, K., Boentert, M., Berger, P., Bonneick, S., Wessig, C., Toyka, K.V., Young, P., and Suter, U. (2007) Mtmr13/Sbf2-deficient mice: an animal model for CMT4B2. Hum. Mol. Genet., 16, 2991-3001.
81. Lorenzo, O., Urbe, S., and Clague, M.J. (2006) Systematic analysis of myotubularins: heteromeric interactions, subcellular localisation, and endosome related functions. J. Cell. Sci., 119, 2953-2959.
82. Laporte, J., Blondeau, F., Buj-Bello, A., Tentler, D., Kretz, C., Dahl, N., and Mandel, J.L. (1998) Characterization of the myotubularin dual specificity phosphatase gene family from yeast to human. Hum. Mol. Genet., 7, 1703- 1712.
83. Bolis, A., Coviello, S., Bussini, S., Dina, G., Pardini, C., Previtali, S.C., Malaguti, M., Morana, P., Del Carro, U., Feltri, M.L., et al. (2005) Loss of Mtmr2 phosphatase in Schwann cells but not in motor neurons causes Charcot-Marie-Tooth type 4B1 neuropathy with myelin outfoldings. J. Neurosci., 25, 8567-8577.
84. Fabre, S., Reynaud, C., and Jalinot, P. (2000) Identification of functional PDZ domain binding sites in several human proteins. Mol. Biol. Rep., 27, 217-224.
85. Lee, H.W., Kim, Y., Han, K., Kim, H., and Kim, E. (2010) The phosphoinositide 3-phosphatase MTMR2 interacts with PSD-95, and maintains excitatory synapses by modulating endosomal traffic. J. Neurosci., 30, 5508-5518.
86. Yu, J., He, X., Chen, Y.G., Hao, Y., Yang, S.,Wang,L., Pan, L., and Tang, H. (2013) Myotubularin-related protein 4 (MTMR4) attenuates BMP/Dpp signaling by dephosphorylation of Smad proteins. J. Biol. Chem., 288, 79- 88.
87. Yu, J., Pan, L., Qin, X., Chen, H., Xu, Y., Chen, Y., and Tang, H. (2010) MTMR4 attenuates transforming growth factor beta (TGFbeta) signaling by dephosphorylating R-Smads in endosomes. J. Biol. Chem., 285, 8454- 8462.
88. Hjelmeland, A.B., Hjelmeland, M.D., Shi, Q., Hart, J.L., Bigner, D.D., Wang, X.F., Kontos, C.D., and Rich, J.N. (2005) Loss of phosphatase, and tensin homologue increases transforming growth factor beta-mediated invasion with enhanced SMAD3 transcriptional activity. Cancer Res, 65, 11276-11281.
89. Beck, S.E., and Carethers, J.M. (2007) BMP suppresses PTEN expression via RAS/ERK signaling. Cancer Biol. Ther., 6, 1313-1317.
90. Yang, Y., Zhou, F., Fang, Z., Wang, L., Li, Z., Sun, L., Wang, C., Yao, W., Cai, X., Jin, J., et al. (2009) Post-transcriptional, and post-translational regulation of PTENby transforming growth factor-beta1. J. Cell Biochem., 106, 1102-1112.
91. Guo, L., Martens, C., Bruno, D., Porcella, S.F., Yamane, H., Caucheteux, S.M., Zhu, J., and Paul, W.E. (2013) Lipid phosphatases identified by screening a mouse phosphatase shRNA library regulate T-cell differentiation, and Protein kinase B AKT signaling. Proc. Natl Acad. Sci. USA, 110, E1849-E1856.
92. Firestein, R., and Cleary, M.L. (2001) Pseudo-phosphatase Sbf1 contains an N-terminal GEF homology domain that modulates its growth regulatory properties. J. Cell Sci., 114, 2921-2927.
93. Pagliarini, D.J., Wiley, S.E., Kimple, M.E., Dixon, J.R., Kelly, P., Worby, C.A., Casey, P.J., and Dixon, J.E. (2005) Involvement of a mitochondrial phosphatase in the regulation of ATP production, and insulin secretion in pancreatic beta cells. Mol. Cell, 19, 197-207.
94. Zeng, Q., Si, X., Horstmann, H., Xu, Y., Hong, W., and Pallen, C.J. (2000) Prenylation-dependent association of protein-tyrosine phosphatases PRL-1, -2, and -3 with the plasma membrane, and the early endosome. J. Biol. Chem., 275, 21444-21452.
95. Ríos, P., Li, X., and Kohn, M. (2013) Molecular mechanisms of the PRL phosphatases. FEBS J., 280, 505-524.
96. McParland, V., Varsano, G., Li, X., Thornton, J., Baby, J., Aravind, A., Meyer, C., Pavic, K., Rios, P., and Kohn, M. (2011) The metastasis-promoting phosphatase PRL-3 shows activity toward phosphoinositides. Biochemistry, 50, 7579-7590.
97. Saarikangas, J., Zhao, H., and Lappalainen, P. (2010) Regulation of the actin cytoskeleton-plasma membrane interplay by phosphoinositides. Physiol. Rev., 90, 259-289.
98. Zimmerman, M.W., Homanics, G.E., and Lazo, J.S. (2013) Targeted deletion of the metastasis-associated phosphatase Ptp4a3 (PRL-3) suppresses murine colon cancer. PLoS ONE, 8, e58300.
99. Conduit, S.E., Dyson, J.M., and Mitchell, C.A. (2012) Inositol polyphosphate 5-phosphatases; new players in the regulation of cilia, and ciliopathies. FEBS Lett., 586, 2846-2857.
100. Hakim, S., Bertucci, M.C., Conduit, S.E., Vuong, D.L., and Mitchell, C.A. (2012) Inositol polyphosphate phosphatases in human disease. Curr. Top. Microbiol. Immunol., 362, 247-314.
101. Zhang, J., Guan, Z., Murphy, A.N., Wiley, S.E., Perkins, G.A., Worby, C.A., Engel, J.L., Heacock, P., Nguyen, O.K., Wang, J.H., et al. (2011) Mitochondrial phosphatase PTPMT1 is essential for cardiolipin biosynthesis. Cell Metab., 13, 690-700.
102. Niemi, N.M., Lanning, N.J., Westrate, L.M., and MacKeigan, J.P. (2013) Downregulation of the mitochondrial phosphatase PTPMT1 is sufficient to promote cancer cell death. PLoS ONE, 8, e53803.
103. Shen, J., Liu, X., Yu, W.M.,Liu, J., Nibbelink, M.G., Guo,C., Finkel, T., and Qu, C.K. (2011) A critical role of mitochondrial phosphatase Ptpmt1 in embryogenesis reveals a mitochondrial metabolic stress-induced differentiation checkpoint in embryonic stem cells. Mol. Cell Biol., 31, 4902-4916.
104. Pagliarini, D.J., Worby, C.A., and Dixon, J.E. (2004) A PTEN-like phosphatase with a novel substrate specificity. J. Biol. Chem., 279, 38590- 38596.
105. Andersen, J.N., Mortensen, O.H., Peters, G.H., Drake, P.G., Iversen, L.F., Olsen, O.H., Jansen, P.G., Andersen, H.S., Tonks, N.K., and Moller, N.P. (2001) Structural, and evolutionary relationships among protein tyrosine phosphatase domains. Mol. Cell Biol., 21, 7117-7136.
106. Begley, M.J., Taylor, G.S., Kim, S.A., Veine, D.M., Dixon, J.E., and Stuckey, J.A. (2003) Crystal structure of a phosphoinositide phosphatase, MTMR2: insights into myotubular myopathy, and Charcot-Marie-Tooth syndrome. Mol. Cell, 12, 1391-1402.
107. Hackney, C.M., and Furness, D.N. (2013) The composition, and role of cross links in mechanoelectrical transduction in vertebrate sensory hair cells. J. Cell. Sci., 126, 1721-1731.